5-chloro-2-fluoro-4-(2-(pyridazin-4-yl)-4-(trifluoromethyl)phenoxy)-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide

ID: ALA2324776

Chembl Id: CHEMBL2324776

Cas Number: 1235406-03-7

PubChem CID: 46841787

Max Phase: Preclinical

Molecular Formula: C19H10ClF4N5O3S2

Molecular Weight: 531.90

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  O=S(=O)(Nc1nncs1)c1cc(Cl)c(Oc2ccc(C(F)(F)F)cc2-c2ccnnc2)cc1F

Standard InChI:  InChI=1S/C19H10ClF4N5O3S2/c20-13-6-17(34(30,31)29-18-28-27-9-33-18)14(21)7-16(13)32-15-2-1-11(19(22,23)24)5-12(15)10-3-4-25-26-8-10/h1-9H,(H,28,29)

Standard InChI Key:  ZAGGUCLXSCVDCK-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA2324776

   Benzenesulfonamide, 5-chloro-2-fluoro-4-[2-(4-pyridazinyl)-4-(trifluoromethyl)phenoxy]-N-1,3,4-thiadiazol-2-yl-

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 531.90

Molecular Weight (Monoisotopic): 530.9850

AlogP: 5.40

#Rotatable Bonds: 6

Polar Surface Area: 106.96

Molecular Species: ACID

HBA: 8

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 6.35

CX Basic pKa: 3.09

CX LogP: 3.49

CX LogD: 2.76

Aromatic Rings: 4

Heavy Atoms: 34

QED Weighted: 0.33

Np Likeness Score: -1.84

References

1. Norinder U, Ek ME..  (2013)  QSAR investigation of NaV1.7 active compounds using the SVM/Signature approach and the Bioclipse Modeling platform.,  23  (1): [PMID:23177785] [10.1016/j.bmcl.2012.10.102]

2. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

3. Swain NA, Batchelor D, Beaudoin S, Bechle BM, Bradley PA, Brown AD, Brown B, Butcher KJ, Butt RP, Chapman ML, Denton S, Ellis D, Galan SRG, Gaulier SM, Greener BS, de Groot MJ, Glossop MS, Gurrell IK, Hannam J, Johnson MS, Lin Z, Markworth CJ, Marron BE, Millan DS, Nakagawa S, Pike A, Printzenhoff D, Rawson DJ, Ransley SJ, Reister SM, Sasaki K, Storer RI, Stupple PA, West CW..  (2017)  Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.,  60  (16): [PMID:28682065] [10.1021/acs.jmedchem.7b00598]

4. Tess DA,Eng H,Kalgutkar AS,Litchfield J,Edmonds DJ,Griffith DA,Varma MVS.  (2020)  Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs.,  63  (20): [PMID:32985885] [10.1021/acs.jmedchem.0c01033]

Source

Source(2):

• Scientific Literature
• AstraZeneca Deposited Data